CHONGQING, China, July 8, 2024
/PRNewswire/ -- Porton J-STAR today announced that Enabling
Technologies Consortium (ETC) has awarded a two-year contract to
J-STAR to collaborate on "Co-processing Platform Technology."
The primary goal of co-processing is to improve the reliability
and efficiency of drug product manufacturing processes to support
direct compression or continuous manufacturing techniques.
Co-processed APIs offer solutions to challenges like inadequate
powder flow, low bulk density, broad particle size distribution,
and compressibility, facilitating direct compression. When
traditional methods such as API crystallization through solvent
selection, supersaturation control, seeding, or milling techniques
are insufficient, co-processing of API with excipients can
significantly improve the functional properties to overcome these
challenges.
ETC members sought to establish a collaboration with a third
party to develop co-processing platform technology to leverage this
technique to avoid these API crystallization challenges. In order
to select their collaborator, ETC had a public call requesting
proposals for a co‑processing technology platform solution.
Following an extensive and rigorous evaluation of numerous
proposals submitted by industry service providers and academic
institutions, ETC selected Porton J-STAR to deliver commercial
co-processing platform technology to the industry and scientific
community. Under the terms of the Development Contract, ETC member
companies will collaborate with Porton J-STAR to develop the
Co-processing Technology Platform.
"As Porton J-STAR initiates it collaboration with ETC, we
are poised to accelerate drug development, access cutting-edge
technologies, establish industry standards, and enable our
customers and the public to access quality medicines earlier." Dr.
Renee Miao, General Manager of
Porton J-Star remarked.
With this announcement, we are excited to introduce the
"Co-processing Center," led by Dr. San Kiang, the leading expert on
Co-processing and Chief Technology Officer at J-STAR.
About Enabling Technologies Consortium
The Enabling Technologies Consortium (ETC) comprises
pharmaceutical and biotechnology companies working together on
pharmaceutical chemistry, manufacturing, and control (CMC)
challenges. Their goal is to identify, evaluate, develop, and
enhance scientific tools and techniques to support efficient
pharmaceutical development and manufacturing. The consortium's
mission is to proactively identify high-value opportunities for
delivering innovative technologies where a strong business case
exists and collaboration with the broader external community is
essential.
About Porton J-STAR
Founded in 2005, Porton Pharma Solutions Ltd. (Porton) is an
internationally recognized pharmaceutical contract development and
manufacturing organization (CDMO) enabling our global clients to
optimize drug development and manufacturing. We provide custom
development and manufacturing services for Small Molecules,
TIDES and ADCs from pre-clinical to commercial. Porton is
committed to becoming the most open, innovative, and reliable
pharmaceutical service platform in the world and enabling the
public's early access to good medicines. J-STAR is the US R&D
Center of Porton.
CONTACTS:
For
Porton J-STAR: Keith
Dodson, J-STAR Research Inc., a subsidiary of Porton Pharma
Solutions. Email: kdodson@portonusa.com
For ETC:
James Vergis, ETC Secretariat and
Principal Faegre Drinker Biddle and Reath, LLP
Email: james.vergis@faegredrinker.com or
info@etconsortium.org
View original content to download
multimedia:https://www.prnewswire.com/news-releases/porton-j-star-and-enabling-technologies-consortium-collaboration-on-co-processing-platform-technology-development-302189830.html
SOURCE Porton Pharma Solutions